Abstract
Progyny will release its first-quarter 2026 financial results on May 7, 2026 Post Market, with current projections pointing to mid‑single‑digit revenue growth and a meaningful year‑over‑year rebound in per‑share earnings, while investors watch margins, client‑add commentary, and progress on new product initiatives.
Market Forecast
Current projections for the first quarter of 2026 indicate revenue of 326.51 million US dollars, up 6.06% year over year, with adjusted EPS around 0.30, up 58.24% year over year; EBIT is estimated at 41.88 million US dollars, implying a 7.58% year‑over‑year decline, and there is no formal gross‑margin or net‑margin forecast disclosed. The main business is expected to maintain its revenue leadership and stable mix, with attention on membership utilization patterns and client growth to shape gross‑margin outcomes this quarter.
The most promising segment centers on pharmacy benefits services, where revenue leverage to medication volume and regimen intensity typically drives growth; the most recent quarter’s mix implies quarterly pharmacy revenue of 113.15 million US dollars, though segment‑level year‑over‑year growth was not disclosed.
Last Quarter Review
Progyny’s previous quarter delivered revenue of 318.40 million US dollars, gross profit margin of 24.15%, GAAP net profit attributable to common shareholders of 12.49 million US dollars, net profit margin of 3.92%, and adjusted EPS of 0.14, up 16.67% year over year; revenue grew 6.69% year over year and net profit decreased 9.95% quarter on quarter.
A key highlight was operating profitability: EBIT reached 50.02 million US dollars, a year‑over‑year increase of 7.24%, while revenue exceeded internal expectations by 3.56%, showing resilient execution into year‑end. In the main business, fertility benefits services represented 64.48% of quarterly revenue, approximately 205.25 million US dollars, and pharmacy benefits services represented 35.52%, approximately 113.15 million US dollars, indicating a steady revenue mix entering 2026.
Current Quarter Outlook
Fertility Benefits Services
The core benefits offering remains the primary revenue driver, and the quarter’s topline projection of 326.51 million US dollars implies continued demand from existing clients and a solid contribution from annual program resets. Utilization patterns early in the plan year can influence procedure volumes and case starts, which in turn affect both revenue timing and cost of services. With the model geared to outcomes and comprehensive support, case mix and cycle completion rates are two variables that can swing gross profit in either direction quarter to quarter.
From a profitability lens, the projected year‑over‑year decline in EBIT despite revenue growth suggests increased operating investment—such as member support, provider network initiatives, or product enhancements—flowing through the P&L in early 2026. That dynamic means investors may tolerate slightly softer operating margin this quarter as long as revenue and EPS track or exceed expectations and management reaffirms the full‑year profitability glide path. The benefits business tends to see volume clustering around life‑event planning cycles, and commentary on case pipeline progression and employer program utilization will be central to gauging the sustainability of mid‑single‑digit revenue growth.
Client activity is another focus. The cadence of go‑lives and expansions typically influences the pace of benefit utilization and adjacent services uptake. Management’s update on 2026 client additions and retention, plus visibility into the second‑half pipeline, will be critical for assessing whether the benefits line can re‑accelerate above mid‑single‑digit growth in subsequent quarters. Against that backdrop, consensus looks for EPS expansion this quarter on revenue leverage and disciplined cost control, even if operating margin is sequentially mixed.
Pharmacy Benefits Services
Within the current mix, pharmacy benefits services remain positioned to capture incremental growth as medication adherence, regimen complexity, and increased cycles translate into higher prescription volumes. The segment’s quarterly revenue proxy at 113.15 million US dollars, derived from the latest reported mix, underscores its scale and ongoing role in broadening the client value proposition. This line is particularly sensitive to utilization patterns, and a stronger intake of initiated cycles can drive higher pharmacy throughput, albeit at a potential trade‑off with consolidated gross margin due to the inherently lower gross margin profile of pharmacy revenue.
For the first quarter, investors will parse the relationship between mid‑single‑digit consolidated revenue growth and pharmacy mix shifts. If medication volumes and supportive therapies trend above historical seasonality, consolidated gross margin could compress modestly even as EPS advances on scale. Conversely, if case mix tilts toward higher‑margin elements or the benefits line captures favorable outcomes‑linked economics, pharmacy growth can still be accretive at the EPS level as fixed costs are leveraged.
A noteworthy development is the rollout of a fully insured supplemental plan introduced on April 16, 2026, designed to offer comprehensive family‑building and women’s health coverage to smaller employers with predictable costs. While near‑term revenue recognition may be limited by sales cycles and onboarding timelines, the plan broadens addressable customers and should help funnel incremental pharmacy volumes as eligible members engage with treatment plans. Management’s update on early demand signals, contracted lives under this offering, and the expected timeline for first revenue contributions will be closely watched for implications on the pharmacy trajectory in the second half of the year and into 2027.
Key Stock Price Drivers This Quarter
Earnings sensitivity this quarter is most tied to revenue delivery relative to the 326.51 million US dollars marker and EPS versus approximately 0.30. A revenue beat of even low single‑digits can translate into non‑linear EPS upside if expense growth remains paced, while any shortfall likely amplifies investor scrutiny of operating spend given the projected year‑over‑year EBIT decline. The balance between mix and margin is another key lever; higher pharmacy utilization supports top‑line growth but can weigh on consolidated gross margin, so commentary on product mix, pricing, and clinical outcomes will shape post‑print reactions.
Management guidance for 2026 remains the swing factor for multiple expansion. Clear data points on client adds, retention, and new product adoption—especially the fully insured supplemental plan—can underpin confidence in a broader multi‑quarter growth curve. Investors will also pay attention to the cadence of investment spend behind support teams, technology, and network expansion, which influences how quickly operating margins recover from early‑year spending. On balance, if the company affirms a path to sustained revenue growth at or above mid‑single digits with improving EPS power, the stock reaction should skew to how much operating leverage management can credibly deliver through the year.
Finally, qualitative color on cycle dynamics and employer demand will be critical. Updates on case starts, treatment funnel conversion, and benefit utilization rates will help investors calibrate the remainder of 2026. The degree to which these metrics align with the EPS growth signal implied by the 58.24% year‑over‑year increase this quarter will determine whether the market views any EBIT pressure as a transitory investment effect or a sign of structural margin constraints.
Analyst Opinions
Bullish views outweigh bearish commentary in the period since January 2026. One prominent broker reiterated a Buy rating while trimming its price target to 28.00 US dollars, citing an expectation for mid‑single‑digit revenue growth this quarter and reinforcing confidence in the company’s earnings power as operating expenses are absorbed. Across covering brokers, the average recommendation trends toward Buy with an average price target around 30.00 US dollars, indicating that most institutions anticipate execution consistent with or ahead of the current quarter’s revenue and EPS markers.
The bullish camp’s case hinges on several pillars. First, consensus revenue of 326.51 million US dollars accompanied by an EPS projection near 0.30 suggests sufficient scale to expand per‑share earnings even if consolidated gross margin is stable to slightly lower on mix. That earnings setup reflects disciplined cost control and incremental leverage from recurring benefits and pharmacy throughput. Second, client adoption and program expansions are expected to underpin visibility into the mid‑term revenue base, with management’s update on 2026 client adds likely to validate the durability of demand. Third, the launch of a fully insured supplemental plan aimed at small employers expands the product suite and can seed new client cohorts, providing a meaningful second‑half and 2027 call option that is not yet fully embedded in near‑term estimates.
A notable aspect of the bullish argument is the asymmetry around EBIT and EPS. While EBIT is forecast to decline 7.58% year over year, bulls view this as a timing effect of investment and mix rather than deterioration in unit economics. If revenue lands close to or above 326.51 million US dollars and management guides to steadier operating margin progression across 2026, earnings can compound from a higher base than the market currently discounts. Commentary pinpointing utilization behavior, cycle completions, and medication regimen intensity will either reinforce or challenge this view, but the central bull case remains that the company can deliver EPS growth in line with the 58.24% year‑over‑year estimate even amid investment.
Bulls also highlight recent execution: the prior quarter’s 6.69% revenue growth and a 3.56% beat versus internal expectations set a constructive starting point for the year, and 50.02 million US dollars of EBIT, up 7.24% year over year, demonstrates operating discipline. With the revenue mix stable—approximately 64.48% from benefits and 35.52% from pharmacy—investors have a clear framework for modeling gross‑margin scenarios against pharmacy volume trajectories. If the mix holds while new initiatives build, sell‑side models that incorporate cautious margin assumptions may prove conservative on EPS, supporting positive estimate revisions.
Looking ahead to the print, bullish analysts are likely to focus on four checkpoints: revenue at or above 326.51 million US dollars, EPS tracking near 0.30 or better, commentary that early demand for the fully insured supplemental plan is constructive with line‑of‑sight to contribution later in 2026, and incremental visibility into client adds and utilization that supports mid‑single‑digit or higher full‑year revenue growth. Meeting or exceeding these checkpoints would validate the prevailing Buy skew in institutional views and strengthen the case for multiple support as the company navigates early‑year operating investment while positioning for margin expansion later in the year.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments